Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025

69 https://tcpharm.orgIn the original publication, an error was identified in Table 2 (Summary of E-R relationships and FDA assessments for ADCs).In the row for datopotamab deruxtecan (2025), interstitial lung disease (ILD) was incorrectly listed under the exposure-safety relationship (ADC) column.The corrected entry is shown below.The authors apologize for this error and any confusion it may have caused. Table 2 (excerpt). Summary of E-R relationships and FDA assessments for ADCs Before correctionAfter correction